Somatropin Dosage and Administration Protocols in Research

Research Disclaimer: Somatropin (recombinant human growth hormone) is sold for in-vitro and laboratory research use. Pharmaceutical somatropin is licensed for specific therapeutic uses; this content addresses research dosing contexts. This content does not constitute medical advice.

Translating growth hormone research requires working across different dosing systems, species, and administration routes. This guide covers the key practical considerations for rhGH (somatropin) dosing in research contexts: unit conversions, dose-response relationships, species differences, and protocol design considerations.

Table of Contents#

1. IU vs. mg: The Conversion
2. Dose-Response Data: GH and IGF-1
3. Species-Specific Considerations
4. Administration Routes
5. Pulsatile vs. Continuous Protocols
6. Protocol Duration and Endpoint Selection
7. Hypophysectomy Models
8. Reconstitution and Storage of rhGH
9. Key References

IU vs. mg: The Conversion#

Growth hormone is historically measured in International Units (IU), not mg. This can cause confusion in research contexts.

The conversion#

• 1 mg rhGH = 3 IU (WHO standardized conversion for somatropin/22 kDa GH)
• 1 IU = 0.333 mg = 333 µg

This conversion is based on a bioassay standard and has been the WHO standard since the 1990s. Older literature used 1 IU = 3 IU by a different standard — always verify the reference standard being used.

Why this matters#

A research protocol specifying "0.1 IU/kg" is equivalent to:

• 0.1 × 333 µg = 33.3 µg/kg

A protocol specifying "10 µg/kg" is equivalent to:

• 10 / 333 × 1 IU/kg = 0.03 IU/kg

Most modern research literature reports doses in µg/kg or mg/kg rather than IU. When replicating older studies that used IU, apply the 1 IU = 333 µg conversion.

Dose-Response Data: GH and IGF-1#

IGF-1 dose-response in rodents#

Dose-response plateaus at high doses because:

1. GHRH and somatostatin feedback counters exogenous GH (in intact animals)
2. GH receptor saturation at pituitary and hepatic level
3. SOCS-protein induction limits JAK2/STAT5 signaling

In hypophysectomized rodents#

Hypophysectomized animals have no endogenous GH and no feedback regulation:

• Dose-response is linear across a wider range (no pituitary feedback)
• IGF-1 starts near undetectable → grows proportionally with rhGH dose
• Common doses: 50–200 µg/kg twice daily for robust IGF-1 restoration
• Full IGF-1 normalization: typically 100–200 µg/kg twice daily × 5–7 days

Species-Specific Considerations#

Cross-species bioactivity#

Human GH is highly species-specific. The GH receptor binding site varies between species:

• Human GH activates human AND rat GHR (because rat GHR binds human GH with reasonable affinity)
• Bovine GH does NOT activate human GHR (incompatible binding)
• Rat GH activates rat GHR but not human GHR efficiently

For rodent research, human rhGH (somatropin) is the standard compound and is appropriate — rat GHR accepts human GH. This is why human-derived rhGH is the standard in rat pharmacology.

Allometric dose scaling#

When translating a human dose to a rodent dose (or vice versa), simple mg/kg scaling does NOT work — metabolic rate and pharmacokinetics differ by body surface area, not weight.

Allometric scaling formula: Rodent dose (mg/kg) = Human dose (mg/kg) × (Human body weight / Rodent body weight)^0.25

For rough guidance:

• A clinical dose of 0.3 mg/kg/week in a 70 kg human → approximately 0.6–1.5 mg/kg/week in a 0.25–0.35 kg rat

Most researchers use empirically validated rat doses rather than allometric calculations — standard IGF-1-normalizing doses in hypophysectomized rats are well established.

Administration Routes#

Subcutaneous (SC) injection#

Standard route for rodent rhGH research. Advantages:

• SC absorption of rhGH is ~70–80% in rodents (adequate bioavailability)
• Easy to administer, less invasive than IV
• Suitable for daily or twice-daily dosing in chronic protocols

Intraperitoneal (IP) injection#

Used as an alternative to SC when:

• Larger injection volumes are needed
• SC injection site is compromised in chronic studies

IP bioavailability is similar to SC (~70%). The absorption may be slightly faster via IP.

Intravenous (IV) bolus#

For acute pharmacokinetic studies — measuring the GH concentration-time profile after a bolus. IV gives immediate, precise exposure. Not practical for chronic protocols.

Osmotic minipump (subcutaneous)#

For continuous (non-pulsatile) GH exposure:

• Delivers a constant rate of rhGH SC
• Produces sustained, non-pulsatile GH levels
• Half-lives in pump: rhGH is stable at 37°C for ~14 days when formulated with BSA carrier
• Used specifically to study continuous vs. pulsatile GH effects (by comparing osmotic pump to daily bolus injection at same total daily dose)

Pulsatile vs. Continuous Protocols#

The distinction between pulsatile (bolus injection) and continuous (minipump) GH delivery is one of the most important design variables in GH research.

Why it matters#

For most body composition research: twice-daily SC bolus injections are preferred (more physiological, greater lipolytic effect, less insulin resistance).

For continuous GH exposure studies: osmotic minipump is the appropriate tool.

Why twice-daily (not once-daily)?#

Endogenous GH has 6–10 pulses per 24 hours. Once-daily injection produces one artificial pulse — not a good mimic. Twice-daily provides two pulses per day and better IGF-1 maintenance than once-daily at the same total dose.

In some research (especially hypophysectomized animals where feedback loops are absent), twice-daily is the standard and produces more consistent IGF-1 maintenance.

Protocol Duration and Endpoint Selection#

Short-term (acute, 1–7 days)#

Purpose: GH pharmacokinetics, IGF-1 dose-response, receptor activation studies

Key endpoints:

• Serum GH (timed samples: 0, 15, 30, 60, 120, 240 min after injection)
• Serum IGF-1 (4–8h and 24h after injection, to capture lag response)
• Hepatic pSTAT5 and IGF-1 mRNA (if sacrificing within 2–4h post-injection)

Medium-term (2–4 weeks)#

Purpose: body composition changes, lean/fat redistribution, bone density initiation

Key endpoints:

• Serum IGF-1 at weeks 1, 2, and 4
• Body weight and composition (DXA or micro-CT)
• Organ weights (liver, muscle, fat depots)
• Glucose tolerance test (confirm insulin sensitivity effects)

Long-term (4–12 weeks)#

Purpose: full body composition, bone density, histology, functional outcomes

Key endpoints:

• All medium-term endpoints
• Bone densitometry (DXA or micro-CT spine + femur)
• Muscle fiber CSA and fiber type by histology
• Functional endpoints (grip strength, running capacity, swim test)
• Safety: organ histology, blood glucose, insulin

Hypophysectomy Models#

Hypophysectomy (surgical pituitary removal) is the gold-standard model for complete GH deficiency research:

Advantages for GH research#

• Eliminates all endogenous GH (and other pituitary hormones: TSH, FSH, LH, ACTH, PRL)
• Allows dose-controlled GH replacement without feedback competition
• Provides a clean GH-deficient baseline for replacement studies

Caveats#

• Multiple hormone deficiencies (not just GH) — thyroid hormone, sex steroids, glucocorticoids also absent
• Requires hormone replacement for non-GH confounds in growth/body comp studies
• Surgical model requires expertise and has post-operative mortality rate

For studies focused purely on GH: supplement with:

• T4 (thyroxine, SC): to replace thyroid hormone
• Cortisol/hydrocortisone: to replace corticosteroids (small dose, enough to prevent adrenal insufficiency)
• Estrogen/testosterone replacement is usually NOT given unless specifically studying sex steroid interaction

Reconstitution and Storage of rhGH#

Reconstitution#

rhGH lyophilizate should be reconstituted with:

• Bacteriostatic water (for multi-dose vials in research): benzyl alcohol preservative prevents bacterial growth; allows multi-week use
• Water for injection: appropriate if the entire vial will be used in a single session

Standard reconstitution volume: yield a concentration of 1–2 mg/mL (3–6 IU/mL) for easy dosing.

Swirl gently — do NOT vortex (proteins denature at air-liquid interfaces with vigorous mixing).

Storage#

Freeze-thaw cycles cause irreversible aggregation of the 22 kDa protein — reconstituted rhGH must not be frozen. For long-term storage of the working solution, use single-use aliquots before reconstitution.

Key References#

1. Bidlingmaier M, Strasburger CJ. (2010). "Growth hormone." Handbook of Experimental Pharmacology, 195:187–200.

2. Clark RG, et al. (1985). "Growth responses of hypophysectomized female rats to bolus versus continuous subcutaneous infusions of recombinant human growth hormone." Journal of Endocrinology, 106(3):281–287.

3. WHO Expert Committee. (1994). "International standards for growth hormone." WHO Technical Report Series.

4. Frystyk J. (2004). "Free insulin-like growth factors — measurements and relationships to growth hormone secretion and glucose homeostasis." Growth Hormone & IGF Research, 14(5):337–375.

Research Use Only: Somatropin and all products referenced are sold exclusively for in-vitro research and laboratory use. Pharmaceutical somatropin is regulated — refer to appropriate regulatory frameworks. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Growth Hormone